The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Share News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

Tue, 28th Nov 2023 14:57

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says two more patients have responded to its Scope study, which brings the number of responders to 11 out of 13 patients. As a result, the objective response rate has increased to 85%. Notes one patient has achieved a complete response following treatment. The study has transitioned into the second stage, and Scancell plans to recruit a further 27 patients, with the aim to achieve at least 18 further responses. The trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Scancell reported in mid-September that SCIB1 combined with checkpoint inhibitors showed an 82% objective response rate. Chief Executive Officer Lindy Durrant says: "The Scope study continues to yield excellent results with two more responders and one of the previous patients now achieving a complete response." Durrant says Scancell now expects the iSCIB1+ cohort to start in the first quarter of 2024."

----------

EnSilica PLC - Abingdon, Oxfordshire-based semiconductor designer and supplier - Says performance in the first half of the financial year ending May 31, has been "resilient", buoyed by continued business momentum and "significant" contracts with "key customers". Remains confident in near-to-medium term prospects. Expects to trade in line with market expectations for financial 2024. EnSilica says analyst consensus currently forecast revenue of GBP22.9 million and earnings before interest, tax, depreciation and amortisation of GBP2.5 million.

----------

Orosur Mining Inc - South America-focused minerals explorer and developer - Says Lithium West joint venture has obtained results from its mapping and sampling programme, noting that "abundant" pegmatites are evident, with lithium superoxide results in excess of 2%. Says two additional licences have been confirmed, with its land position in the key lithium districts expanded to 533 square kilometres. CEO Brad George says: "These outstanding results from our first field program in Nigeria are exciting but not surprising. We pegged these licences with a very clear understanding of the geological processes in play, and so we expected to find lithium. To then confirm this confidence and to find so many lithium bearing pegmatites, some extremely thick, is very positive and bodes well for work on the next 5 licences that is underway now."

----------

Zenith Energy Ltd - Africa and Italy-focused oil and gas company - Signs memorandum of understanding with Nile Services & Logistics Co Ltd to jointly pursue business opportunities involving the construction of fuel products storage tanks, pipelines, and crude oil storage tanks in South Sudan. Zenith will provide technical, financial and managerial expertise in the construction of the tanks, while Nile Services will facilitate business opportunities. Zenith CEO Andrea Cattaneo says: "We are very pleased to have now signed an MoU with Nile SLC, a subsidiary of the national oil company of South Sudan, and we look forward with enthusiasm to jointly exploring opportunities in the midstream domain and beyond, specifically with regards to petroleum product trading activities." Also confirms that it is currently in the advanced phase of negotiating the potential acquisition of oil exploration and development licences in South Sudan.

----------

OptiBiotix Health PLC - York, England-based life sciences company - Inks deal with Ravenswood Ingredients Pty Ltd for the distribution of SlimBiome in Australia and New Zealand. "Ravenswood brings access to the food and beverage markets and will complement existing partner capabilities which are largely focused on the meal replacement market to broaden OptiBiotix's impact in Australia and New Zealand. This is part of a strategy of building partnerships to support expansion of OptiBiotix's geographical footprint with companies who bring national and international capability for highly differentiated value-added ingredients in high growth markets around the world," it says. CEO Stephen O'Hara comments: "We are pleased to announce this agreement with Ravenswood who bring specialised food ingredient expertise as part of the Brenntag group, a global market leader in chemicals and ingredients distribution. This agreement is another example of OptiBiotix working with large partners and extends access to the food and beverage markets within Australia and New Zealand with a company which is part of a group which is a global leader in the ingredients market."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Jan 2021 16:30

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

Read more
11 Jan 2021 17:29

IN BRIEF: OptiBiotix Inks Agreement For Microbiome Products Research

IN BRIEF: OptiBiotix Inks Agreement For Microbiome Products Research

Read more
5 Jan 2021 17:55

UK EXECUTIVE CHANGE SUMMARY: Saga Insurance CEO Resigns After One Year

UK EXECUTIVE CHANGE SUMMARY: Saga Insurance CEO Resigns After One Year

Read more
9 Dec 2020 16:08

UK EXECUTIVE CHANGE SUMMARY: Wizz Poaches From easyJet; New Cenkos CEO

UK EXECUTIVE CHANGE SUMMARY: Wizz Poaches From easyJet; New Cenkos CEO

Read more
18 Nov 2020 14:53

IN BRIEF: OptiBiotix Grants License for Cardiovascular Health Product

IN BRIEF: OptiBiotix Grants License for Cardiovascular Health Product

Read more
18 Nov 2020 12:23

OptiBiotix grants LPLDL licence to Canada's Genuine Health

(Sharecast News) - Life sciences company OptiBiotix Health announced on Wednesday that its wholly-owned subsidiary ProBiotix Health has granted a non-exclusive licence for 'LPLDL' to Genuine Health, for a cardiovascular health product in Canada and the United States.

Read more
12 Oct 2020 14:34

IN BRIEF: OptiBiotix Notes Australia And New Zealand Product Launch

IN BRIEF: OptiBiotix Notes Australia And New Zealand Product Launch

Read more
12 Oct 2020 14:00

OptiBiotix products launch into retail in Australia, New Zealand

(Sharecast News) - Life sciences company OptiBiotix Health announced the launch of meal replacement shakes and bars containing its 'OptiBiome' proprietary weight management technology under the 'Optislim' brand with the Woolworths and Chemist Warehouse retailers, and online, in Australia and New Zealand.

Read more
8 Oct 2020 21:16

UK EXECUTIVE CHANGE SUMMARY: Silence Wants US CFO After Nasdaq Float

UK EXECUTIVE CHANGE SUMMARY: Silence Wants US CFO After Nasdaq Float

Read more
6 Oct 2020 14:36

IN BRIEF: OptiBiotix's ProBiotix Inks Singaporean Deal For CholBiomeX3

IN BRIEF: OptiBiotix's ProBiotix Inks Singaporean Deal For CholBiomeX3

Read more
2 Oct 2020 11:13

OptiBiotix Notes FDA Approval For Investigation Into Partner's New Drug

OptiBiotix Notes FDA Approval For Investigation Into Partner's New Drug

Read more
2 Oct 2020 10:17

OptiBiotix shares rise as partner Seed gets FDA approval

(Sharecast News) - Life sciences company OptiBiotix Health announced on Friday that one of its partners, Seed Health, has received US Food and Drug Administration authorisation for an investigational new drug (IND) application for 'DS-01'.

Read more
24 Sep 2020 12:25

OptiBiotix revenue improves fivefold in first half

(Sharecast News) - Life sciences company OptiBiotix Health reported first-half revenue growth to £0.74m in its first half on Thursday, which was a five times increase in revenues from the first half of 2019.

Read more
24 Sep 2020 12:04

IN BRIEF: OptiBiotix Pretax Loss Narrows, Prepares For Dual Listing

IN BRIEF: OptiBiotix Pretax Loss Narrows, Prepares For Dual Listing

Read more
22 Sep 2020 15:04

IN BRIEF: OptiBiotix Inks SlimBiome License Deal With HiLife Vitamins

IN BRIEF: OptiBiotix Inks SlimBiome License Deal With HiLife Vitamins

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.